SUVODA

Trial wisely

Suvoda eConsent

Real-Time Visibility & Automated Control

1/3

Phase III trials have highest deviations, involving approximately 1/3 of patients in trial[1]

3

Protocols with 3+ amendments add 3 weeks to planned treatment duration, on average[1]

70%

70% of Oncology trials Suvoda supports have at least one amendment[2]

Suvoda's eConsent is an intuitive, flexible electronic informed consent application for clinical trials. Whether on-site or remote, eConsent allows patients, caregivers, and authorized representatives to review consent documentation, while providing consistency and compliance.

Leveraging seamless integration with the IRT, eConsent enables real-time visibility into and automated control over the patient consent process — helping to reduce regulatory risk, administrative burden, and study duration and expenses created by mid-study consent requirements.

SEAMLESS ARCHITECTURE: eCONSENT + IRT

+ Provides a single platform view, resulting in full data visibility and risk mitigation
+ Automates decision-making with seamless interoperability between the IRT system and eConsent application
+ Tracks consents, screening and randomization data in one place
+ Enables deployment of the eConsent application within 3-5 business days of your consent document approval

SUVODA

LEARN MORE

Visit suvoda.com
to learn about our solutions

BENEFITS

VISIBILITY

Integrated reporting provides real-time visibility into consent status across sites within your IRT

CONTROL

Workflows are fully streamlined with a completely controlled process safeguarding quality and compliance

SPEED

Alignment with current study team processes enables faster deployment within days of your document approval

FLEXIBILITY

Accommodate a variety of consent methods and types to meet differing requirements across trials and countries

INTUITIVE INTERFACE

Smoothly move between IRT activities and eConsent tasks with minimal additional user training

REDUCED REGULATORY RISK

Verify consent remotely and take early corrective action to reduce the risk of excluded patients and discarded data

KEY FEATURES

+ PDF upload of approved consent documents
+ Electronic signature, wet ink upload, and print & sign
+ Available on multiple devices — web-based, on-site, or patient device
+ Multilingual capability



[1] January/February 2022 Impact Report, Tufts Center for the Study of Drug Development.
[2] Suvoda data and customer interviews

suvoda.com | info@suvoda.com